Mark Emberton
As seen in:
BBC,
Nature,
The Telegraph,
PLOS Medicine,
ScienceDirect,
JAMA Oncology,
OncLive,
European Urology,
BJU International,
Urology Times
and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mark Emberton
Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective HEAT and ICE Registries
Keywords Ablation Cryotherapy Focal ablation Focal therapy HIFU Localised Nonmetastatic Prostate cancer What does this study add? Focal therapy using HIFU or cryotherapy is increasingly used to treat nonmetastatic prostate cancer.
Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM) : International Consensus Recommendations
|
Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations Abstract Importance Magnetic resonance imaging (MRI) is routinely used in prostate cancer diagnosis, but there is uncertainty about its optimal use in population-level screening. Objective To provide consensus recommendations on the acquisition, interpretation, and reporting of prostate MRI for cancer screening.
By Nikhil Mayor, Alexander Light, Archana Gopalakrishnan, Emma Cullen, Natasha Thorley, Tristan Barrett, Tim Dudderidge, Mark Emberton, Francesco Giganti, Aiman Haider, Masoom A. Haider, Amish Lakhani, Caroline Moore, Tobias Nordström, Anwar R. Padhani, Ivo G. Schoots, Andrew Smith, Henry Tam, Massimo Valerio, Sadhna Verma, Samuel J Withey, Shonit Punwani, Taimur T. Shah, Jan van der Meulen, Hashim U. Ahmed, Francesca Rawlins, Varsha Sonigra-Patel, Oliver Hulson
|
JAMA Oncology
Verified
Imaging in focal therapy: advanced ultrasound imaging and mpMRI—a comprehensive review - Prostate Cancer and Prostatic Diseases Original
Refining partial gland ablation for localised prostate cancer: the FALCON project
Objectives To provide a contemporary statement on focal therapy (FT) for localised prostate cancer (PCa) from an international and diverse group of physicians treating localised PCa, with the aim of overcoming the limitations of previous consensus statements, which were restricted to early adopters, and to offer direction regarding the various aspects of FT application that are currently not well defined.
Developing and validating development goals towards transforming a global framework for pharmacy practice
Pharmacy practice and pharmaceutical services have continually evolved in response to the dynamic challenges presented by global health concerns.1 Primarily, a paradigm shift from product to patient-centred care marked a crucial milestone in the evolution of the pharmacy profession on a global scale.2 As the world faces significant shifting population demographics, increased comorbidities and medicine complexity and in light of the global pursuit of Universal Health Coverage (UHC)3 - it has...
The FocAL therapy CONsensus (FALCON): enhancing partial gland ablation for localised prostate cancer
Research Letter The FocAL therapy CONsensus (FALCON): enhancing partial gland ablation for localised prostate cancer Lara Rodríguez-Sánchez, Corresponding Author Lara Rodríguez-Sánchez Urology Department, Institut Mutualiste Montsouris, Paris, France Correspondence: Lara Rodríguez-Sánchez, Urology Department, Institut Mutualiste Montsouris, Paris, France.
Prostate cancer detection and complications of MRI-targeted prostate biopsy using cognitive registration, software-assisted image fusion or in-bore guidance: a systematic review and meta-analysis of comparative studies | Prostate Cancer and Prostatic Dise
Abstract Three primary strategies for MRI-targeted biopsies (TB) are available: Cognitive TB (COG-TB), MRI-US Fusion TB (FUS-TB), and In Bore TB (IB-TB). Despite nearly a decade of practice, a consensus on the preferred approach is lacking, with previous studies showing comparable PCa detection rates among the three methods.
From BPH to male LUTS: a 20-year journey of the EAU guidelines - Prostate Cancer and Prostatic Diseases
This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 4 print issues and online access $259.00 per year only $64.75 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Additional access options: Log in Learn about institutional subscriptions Read our FAQs Contact customer support References Woolf SH, Grol R, Hutchinson A,...
Prostatic high-resolution micro-ultrasound: an attractive step-forward in the management of prostate cancer patients - Prostate Cancer and Prostatic Diseases
Prostatic high resolution micro-ultrasound (MUS) was first described by Pavlovich et al. in 2014 [1]. Thanks to scanners operating at high frequency (29 MHz) and the resulting real-time spatial resolution up to 70 microns (near 300% higher than existing platforms) it allows to better evaluate the microstructures and tissue planes.
An update from the ReIMAGINE Prostate Cancer Risk Study (NCT04060589): A prospective cohort study in men with a suspicion of prostate cancer who are referred onto a magnetic resonance imaging-based diagnostic pathway with donation of tissue, blood, and ur
To read this article in full you will need to make a payment Subscribe to European Urology References National Institute for Health and Care Excellence Prostate cancer: diagnosis and management. NICE guideline NG131. Mottet N. van den Bergh R.C.N. Briers E. et al. EAU-EANM-ESUR-ESTRO-SIOG guidelines on prostate cancer. Fulgham P.F. Rukstalis D.B. Rubenstein J.N. et al.
Prostate cancer and the human papilloma virus: causative association, role of vaccines, and the impact of the COVID-19 pandemic
Abstract Prostate cancer affects a significant proportion of men worldwide. Evidence from genetic and clinical studies suggests that there may be a causal association between prostate cancer and the human papilloma virus (HPV). As HPV is a vaccine-preventable pathogen, the possibility of a role in prostate cancer causation may reinforce the importance of effective HPV vaccination campaigns.
Re: Simpa S. Salami, Jeffrey J. Tosoian, Srinivas Nallandhighal, et al. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study
Using longitudinal data from a historic cohort, Salami et al [] report on a possible evolutionary process whereby low-grade prostate cancer acquires the histologic phenotype of high-grade prostate cancer. They used next-generation sequencing to confirm that the same cancer focus was sampled at two different time points. The authors should be congratulated for their contribution to the growing field of cancer evolution.
Reply to Francesco Montorsi, Giorgio Gandaglia, Nicola Fossati, Andrea Salonia, and Alberto Briganti’s Letter to the Editor re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surve
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. We thank the authors for their comments on our paper [1]. We agree that in the new world of magnetic resonance imaging before first biopsy for all men, we would hope that surveillance of non-visible prostate cancer will reduce, as these men would avoid the burden of diagnosis entirely.
Reply to Carissa E. Chu, Peter E. Lonergan, and Peter R. Carroll’s Letter to the Editor re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large
Publication History Published online: July 08, 2020Accepted: June 12, 2020;
Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS Study
Abstract Background Multiparametric magnetic resonance imaging (MP-MRI) is established in the diagnosis of prostate cancer, but the need for enhanced sequences has recently been questioned. Objective To assess whether dynamic contrast-enhanced imaging (DCE) improves accuracy over T2 and diffusion sequences.
Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study
Loading metrics Open Access Peer-reviewed Research Article Tom Callender , Mark Emberton, Steve Morris, Ros Eeles, Zsofia Kote-Jarai, Paul D. P. Pharoah, Nora Pashayan Tom Callender, Mark Emberton, Steve Morris, Ros Eeles, Zsofia Kote-Jarai, Paul D. P.
Viewpoint: Prostate cancer screening test 'in sight'
Image copyright Getty Images Image caption MRI scans can safely reduce the numbers of men needing an invasive biopsy A large new trial is testing whether MRI scans could be an effective way to screen men for prostate cancer, in a similar way to mammograms offered to women to check for breast cancer. In this article for the BBC, leading expert Prof Mark Emberton explains why finding a suitable screening method for this common male cancer is vital but has proved difficult so far.
Viewpoint: Prostate cancer screening test 'in sight'
By Prof Mark Emberton Professor of Interventional Oncology, UCL Image copyright Getty Images Image caption MRI scans can safely reduce the numbers of men needing an invasive biopsy A large new trial is testing whether MRI scans could be an effective way to screen men for prostate cancer, in a similar way to mammograms offered to women to check for breast cancer.
Editorial: Translating cost-utility modelling into the real world – the case of focal high-intensity focused ultrasound and active surveillance - BJUI
Rate this article: Editorial: Translating cost-utility modelling into the real world – the case of focal high-intensity focused ultrasound and active surveillance 17 views Health economic modelling is always a challenge. The inputs are never quite what we want them to be. The literature that we have at our disposal suffers from the inevitable deficiencies of lack of maturity, ever diminishing relevance, and questionable applicability as practice evolves.
Magnetic Resonance Imaging Should Be Used in the Active Surveillance of Patients with Localised Prostate Cancer
Veeru Kasivisvanathan x Search for articles by this author Affiliations Division of Surgery and Interventional Science, University College London, London, UK Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK British Urology Researchers in Surgical Training (BURST) Research Collaborative, London, UK Correspondence Corresponding author. University College London, Charles Bell House, 43–45 Foley Street, London W1W 7TS, UK. Tel. +44 207 6799092.
Reply to Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti’s Letter to the Editor, re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Ca
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. It is clear that magnetic resonance imaging (MRI)-targeted biopsies are important in the diagnosis of clinically significant prostate cancer in men with no prior biopsy, prior negative systematic biopsy, or those on active surveillance [1].
Editorial: Dropping the GAD – just a fad? - BJUI
It is not without irony that, at the very moment that the UK’s National Institute for Health and Care Excellence (NICE) is poised to ratify the recommendation that multiparametric MRI (mpMRI) be introduced into the prostate cancer diagnostic pathway, we are seeking to significantly modify the very intervention on which they are about to provide judgement on [1].
Multiparametric MRI for prostate cancer diagnosis: current status and future directions
Abstract The current diagnostic pathway for prostate cancer has resulted in overdiagnosis and consequent overtreatment as well as underdiagnosis and missed diagnoses in many men. Multiparametric MRI (mpMRI) of the prostate has been identified as a test that could mitigate these diagnostic errors.
To see or not to see - what renders prostate cancer visible?
Multiparametric MRI (mpMRI) has revolutionized prostate cancer diagnosis and risk stratification, but the question remains regarding what it is that we see (or don’t see) on mpMRI. A new study by Houlahan and colleagues now offers insight into the molecular characteristics of a tumour that influence mpMRI visibility. Access optionsAccess options Subscribe to Journal Get full journal access for 1 year $213.00 only $17.75 per issue All prices are NET prices. VAT will be added later in the checkout.
Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91 - European Urology
We would like to raise some issues concerning the article by van der Poel et al. [1x[1]van der Poel, H.G., van den Bergh, R.C.N., Briers, E. et al. Focal therapy in primary localised prostate cancer: the European Association of Urology position in 2018. Eur Urol. 2018; 74: 84–91Google ScholarSee all References][1].First, this paper seems to reflect only their position as we find no evidence that the authors sought to investigate the opinion of the European Association of Urology (EAU).
“Don’t Let the Perfect Be the Enemy of the Good”: Time to Embrace Magnetic Resonance Imaging Before First Prostate Biopsy
Drs. Gorin and Walsh [1][1] ask “Are we there yet?” regarding magnetic resonance imaging (MRI) before first prostate biopsy. The editorial is welcome, and the question important.
Editorial: Has tailored, tissue‐selective tumour ablation in men with prostate cancer come of age?
There are two principal challenges that face the growing number of clinical investigators that are evaluating tissue‐preserving therapies in men with prostate cancer. The first is that every man’s prostate is different. So different and so unique are the personal attributes of a man’s prostate that it would, just like the iris or fingerprint, qualify as a unique identifier. It is just a few practical considerations that prevent it from doing so.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mark
Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack